Targeting Coronavirus Protease Could Have Dual Effect

  • Author: ChemistryViews.org
  • Published: 07 August 2020
  • Copyright: Wiley-VCH GmbH
  • Source / Publisher: Nature/Springer Nature Limited
thumbnail image: Targeting Coronavirus Protease Could Have Dual Effect

The COVID-19 pandemic is caused by the coronavirus SARS-CoV-2. Certain enzymes, called viral proteases, are essential for the replication of the virus. SARS-Cov-2, in particular, relies on its main protease (Mpro/3CLpro) and the papain-like protease (PLpro). Papain-like proteases are not only important for virus replication, but can also act on proteins that regulate the host's innate immune pathways, such as ubiquitin and interferon-stimulated gene 15 (ISG15). This makes PLpro a promising target for COVID-19 drugs.


Ivan Dikic, Goethe University, Max Planck Institute of Biophysics, and Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), all Frankfurt am Main, Germany, and colleagues have investigated the biochemical, structural, and functional properties of the PLpro of the SARS-CoV-2 virus (SCoV2-PLpro) and compared them to those of the equivalent enzyme of the related SARS virus (SCoV-PLpro).


Using cell-culture-based experiments, the team found that the two enzymes have different substrate preferences. SCoV2-PLpro preferentially cleaves off the protein ISG15 from substrates and SCoV-PLpro predominantly targets ubiquitin chains. The team determined the crystal structure of a SCoV2-PLpro–ISG15 complex (pictured) and found certain protein residues that lead to a high affinity for ISG15 in SCoV2-PLpro. The resulting higher activity of SCoV2-PLpro for the cleavage of ISG15 leads to a greater inhibition of type I interferon production. Type I interferons are important for the activity of the immune system.


The team looked for inhibitors that could inhibit SCoV2-PLpro and tested GRL-0617, a naphthalene-based inhibitor originally developed against SCoV-PLpro. They found that GRL-0617 effectively blocked the enzyme, as well as overall SARS-CoV-2 virus replication. According to the researchers, such inhibitors of SCoV2-PLpro may lead to new COVID-19 drugs with a dual effect—blocking virus replication and promoting immunity in the host via an interferon pathway.



Also of Interest

  • Collection: SARS-CoV-2 Virus
    What we know about the new coronavirus and COVID-19
  • LitCovid
    Curated literature hub for tracking up-to-date scientific information about COVID-19
  • Many publishers and other entities have signed a joint statement to ensure that COVID-19 research findings and data are shared rapidly and openly

 

 

Article Views: 1308

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH